ATLANTA, GA--(Marketwire - October 16, 2007) - MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company’s drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C.
